Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
  • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
  • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D233/44—Nitrogen atoms not forming part of a nitro radical
  • C07D233/52—Nitrogen atoms not forming part of a nitro radical with hetero atoms directly attached to said nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
  • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine

Definitions

• R and R are each hydrogen or lower alkyl
• alkylene containing two to three carbon atoms and when joined together form alkylene containing two to three carbon atoms, and X is phenyl substituted by at least one halogen atom, and the salts thereof with pharmaceutically acceptable acids.
• R and R which may be the same or different, are each hydrogen atoms or lower alkyl and when R, and R are joined together form alkylene containing two or three carbon atoms and X is phenyl substituted by one or more halogen atoms; and the salts thereof with physiologically compatible acids.
• the new compounds (I) are valuable pharmaceuticals and canbe successfully used for the regulation of. the blood pressure and are particularly suitable for use in the treatment of hypertonias.
• the new guanidine derivatives (I) can be prepared, for example, by the reaction of a hydrazine having the formula:
• R has the same significance as given above, or if R, and R are hydrogen'or lower alkyl, by the reaction of a compound having the-formula:
• R is hydrogen or lower alkyl and X and have the same meanings as given above, with a compound having the formula:
• Tetrahydrofuran has proved to be particularly useful as a polar, inert solvent.
• reaction products is carried out by converting the same by the conventional methods into their physiologically compatible salts, for example, by neutralization with an appropriate organic or inorganic acid.
• physiologically compatible salts there may be mentioned, in particular, the hydrochlorides, hydrobromides, sulfates, phosphates, tartrates, citrates and oxalates of the free bases (I).
• EXAMPLE 2 (3-chloroanilino)-guanidine 7.1 g m-chlorophenyl-hydrazine (0.05 mol) were first heated, while passing nitrogen through the mixture, with 7.7 g S-methyl-isothiuronium bromide for 30 minutes at C and then for 30 minutes at C.
• the compounds of the invention constitute potent antihypertensive agents.
• the compounds have proved particularly effective in the treatment of patients with severe or sustained elevation of blood pressure, particularly diastolic pressure.
• the compounds are suitable for use in almost all forms of fixed and progressive hypertensive disease, including that in which blood pressure is moderately elevated.
• the compounds have also proved efiective in renal hypertension, including hypertension secondary to pyelonephritis, glomerulonephritis and renal amylordosis.
• the compounds can be administered orally, as pills, tablets, capsules, powders and the like.
• the preferred form of oral administration is as a tablet containing 10 to 25 mg of active compound.
• the compounds can also be administered parenterally.
• injection solutions containing 10 mg/ml of injection solution are preferred.
• the dosage schedule is entirely dependent on the condition of the patient, his response to the treatment and whether or not he is ambulatory or hospitalized.
• the treatment should be begun with small doses (10 mg) and increased gradually depending upon the patients response.
• the dosage can be increased at 5 to 7 day intervals until an average daily dose of 25 to 50 mg is reached. Only one dose a day is usually required.
• Rats each weighing 250-300 g were used as test animals. Experimental hypertension was induced in these animals by administering to them over a 4 week period ll-desoxycorticosterone-acetate (5 mg-twice weekly subcutaneously and by supplying them with a feed containing 10 percent sodium chloride. After this period, during which experimental high blood pressure had been achieved, an arterial tonometer catheter was surgically implanted into the carotid artery of each of the animals. Blood pressure measurements were carried out using an electromechanical pressure converter (Statham element) and a direct writing system (Schwarzer system) for recording the same. After the control values had been determined, the animals were given the test substance dissolved in physiological saline, the test drugs being supplied by an esophageal catheter.
• guanethidine (Ismelin Ciba) [2-(octahydro-l-azocinyl)-ethyl]-guanidine sulfate was used.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Applications Claiming Priority (1)

Publications (1)

Family

ID=5699892

Family Applications (1)

Country Status (9)

Cited By (3)

Families Citing this family (2)

Citations (1)

Family Cites Families (1)

• 1968
  • 1968-07-09 DE DE1768867A patent/DE1768867C3/de not_active Expired
• 1969
  • 1969-05-27 US US828366A patent/US3683023A/en not_active Expired - Lifetime
  • 1969-07-03 CA CA056,092A patent/CA954142A/en not_active Expired
  • 1969-07-07 GB GB34186/69A patent/GB1217805A/en not_active Expired
  • 1969-07-07 FI FI692008A patent/FI50114C/sv active
  • 1969-07-07 CH CH1034069A patent/CH511817A/de not_active IP Right Cessation
  • 1969-07-08 FR FR6923147A patent/FR2012562A1/fr not_active Withdrawn
  • 1969-07-08 NL NL6910469A patent/NL6910469A/xx unknown
  • 1969-07-08 AT AT655569A patent/AT292010B/de not_active IP Right Cessation

Patent Citations (1)

Non-Patent Citations (1)

Also Published As

Similar Documents